Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Recruiting now · Phase 2

Conditions studied: Chemoradiotherapy

In brief

To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.

Key facts

Study ID

NCT06667622

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

40

Starts

2024-05-29

Expected to finish

2026-07-20

Last updated by the study team

2024-10-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically or cytologically confirmed non-small cell lung cancer.
• Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
• ECOG PS 0-2
• Adequate organ and bone marrow function.

You may not qualify if…

• History of previous radiotherapy.
• The previous immune-related pneumonitis ≥ grade 2.
• Local lesions require surgery.
• History of another primary malignancy.
• History of active primary immunodeficiency.
• Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.
• For any unmitigated toxicity during pre-study chemoradiotherapy.

Where it is running

• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.